BioSpace News Archive

Drug Development

All Blue Ups the Ante after Zymeworks Rejects Bid

Zymeworks increased its stake in the company to 6.9%, slightly under 4 million shares, and options with shares popped 13% after the original bid and are up another 10%.

May 27, 2022
·
3 min read
·
Mark Terry
Drug Development

Genentech Announces Optimistic Data in Aggressive DLBCL

Genentech announced new data related to its investigational CD20xCD3 T-cell engaging bispecific antibody intended to treat relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).

May 27, 2022
·
3 min read
·
Haley Shasteen
Career Advice

The Top 3 Most Common Mistakes on LinkedIn

BioSpace sat down with Gregg Burkhalter, a LinkedIn Expert, for a quick Q&A about the three most common LinkedIn mistakes and how they can affect your personal brand.

May 27, 2022
·
5 min read
·
Porschia Parker-Griffin
Career Advice

What to Expect From a Pharma Interview

Candice Richards, the Manager of Talent Acquisition at Kyowa Kirin North America, shed some light on what to expect from a pharma interview and how to effectively prepare.

May 27, 2022
·
4 min read
·
Kaley Lefevre
Business

Moderna CEO Joins List of Billionaires Committed to Philanthropy

Bancel’s most recent statements suggest he’s interested in more philanthropy than just his most recent stock option sales.

May 27, 2022
·
3 min read
·
Mark Terry
Molecular Diagnostics Market Size, Share, Growth, Report 2022-2030

According to Vision Research Reports, the Molecular Diagnostics market size is expected to hit around US$ 59.3 billion by 2030 and expected to grow at a CAGR of 4.9% during forecast period 2021 to 2030.

May 27, 2022
·
9 min read
Drug Development

Axcella Shifts Focus to Long COVID, NASH Amid Leadership Losses

Axcella is prioritizing its clinical development portfolio to focus on its investigative assets for COVID-19 and non-alcoholic steatohepatitis (NASH) after abrupt leadership resignations.

May 27, 2022
·
3 min read
·
Alex Keown
Drug Development

Clinical Catch-Up: 3’s the Charm for Pfizer-BioNTech Vaccine in Kids & More

A roundup of last week’s top clinical trial announcements and news, including updates from Pfizer, BioNTech, Ocugen and more.

May 27, 2022
·
10 min read
·
Mark Terry
Drug Development

TikoMed Touts “Disease-modifying” Potential for ALS Asset

TikoMed’s contribution to the fight is ILB, a novel patented formulation of a modified glycosaminoglycan that works to tackle ALS through neurotrophic and myogenic effects.

May 27, 2022
·
2 min read
·
Hayley Shasteen
Drug Development

Clinical Hold Turns out to be Serendipitous for Protagonist’s PV Program

Protagonist Therapeutics announced updated promising data from its phase II Revive clinical trial, which is evaluating the safety and efficacy of rusfertide in patients with polycythemia vera (PV).

May 27, 2022
·
2 min read
·
Jazmine Colatriano M.S.